Krystal Biotech, Inc. (BIT:1KRYS)

Market Cap	4.15B
Revenue (ttm)	305.86M
Net Income (ttm)	124.94M
Shares Out	n/a
EPS (ttm)	4.18
PE Ratio	33.25
Forward PE	23.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17
Average Volume	3
Open	138.85
Previous Close	140.75
Day's Range	138.65 - 138.85
52-Week Range	110.10 - 149.20
Beta	n/a
RSI	63.44
Earnings Date	Nov 3, 2025

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 cl...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 275
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1KRYS

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Financial numbers in USD